IFNG and cancer: These analyses suggest that in all three available datasets, TIGS outperforms TMB and other biomarkers that are based on gene-expression profiling (TIDE, IFNG etc.)in accurately predicting clinical response to immunotherapy and in pan-cancer applicability.